Abstract: A safer live smallpox vaccine, which contains a lowered content of revertants, is provided. A process for manufacturing a live smallpox vaccine which comprises steps of: inoculating a master seed solution of an attenuated vaccinia virus to an appropriate number of containers (1 to n wherein n is an integer) of rabbit kidney cells and incubating them; inoculating a portion of the cultured solution obtained from each container to RK-13 cells and to Vero E6 cells and incubating them to thereby select containers which contain a cultured solution that forms plaques in RK-13 cells but not in Vero E6 cells; and preparing a drug substance of vaccine using the aforementioned cultured solution (working seed solution), and a live smallpox vaccine prepared in the aforementioned process.
Type:
Grant
Filed:
August 6, 2007
Date of Patent:
October 4, 2011
Assignees:
Juridicial Foundation The Chemo-Sero-Therapeutic Research Institute, Japan as represented by Director General of National Institute of Infectious Diseases
Abstract: The present invention provides a vaccine containing a Sendai virus vector encoding a virus protein of an immunodeficiency virus. By intranasally administering a Sendai virus encoding a virus protein of an immunodeficiency virus to a macaque monkey, the present inventors have succeeded in efficiently inducing protective immunity against an immunodeficiency virus. As a result of intranasal inoculation of vaccine, expression of an antigen protein mediated by Sendai virus vector was detected in intranasal mucous membrane and local lymph nodes and antigen-specific cellular immune response was induced at a significant level. No pathological symptom by vaccination was observed. After vaccination, exposure of simian immunodeficiency virus was performed and the effect was examined. As a result, the amount of virus in plasma significantly decreased, compared with that of the control animal. The present invention provides a promising vaccine as an AIDS vaccine.
Type:
Application
Filed:
February 5, 2010
Publication date:
October 21, 2010
Applicants:
DNAVEC Research Inc., Japan as represented by Director General of National Institute of Infectious Diseases
Abstract: The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.
Type:
Application
Filed:
November 7, 2008
Publication date:
September 30, 2010
Applicants:
Japan as Represented by the Director-General of National Institute of Infectious Diseases, The Research Foundation for Microbial Diseases of Osaka University
Abstract: A safer live smallpox vaccine, which contains a lowered content of revertants, is provided. A process for manufacturing a live smallpox vaccine which comprises steps of: inoculating a master seed solution of an attenuated vaccinia virus to an appropriate number of containers (1 to n wherein n is an integer) of rabbit kidney cells and incubating them; inoculating a portion of the cultured solution obtained from each container to RK-13 cells and to Vero E6 cells and incubating them to thereby select containers which contain a cultured solution that forms plaques in RK-13 cells but not in Vero E6 cells; and preparing a drug substance of vaccine using the aforementioned cultured solution (working seed solution), and a live smallpox vaccine prepared in the aforementioned process.
Type:
Application
Filed:
August 6, 2007
Publication date:
July 22, 2010
Applicants:
Juridical Foundation the Chemosero-Therapeutic Research Institute, Japan as represented by Director General of National Institute of Infectious Diseases
Abstract: This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related virus constituting peptides selected from the following peptide groups (a) to (k), respectively: (a) a peptide having an amino acid sequence represented by SEQ ID NO: 1, and the like, (b) a peptide having an amino acid sequence represented by SEQ ID NO: 2, and the like, (c) a peptide having an amino acid sequence represented by SEQ ID NO: 3, and the like, (d) a peptide having an amino acid sequence represented by SEQ ID NO: 4, and the like, (e) a peptide having an amino acid sequence represented by SEQ ID NO: 5, and the like, (f) a peptide having an amino acid sequence represented by SEQ ID NO: 6, and the like, (g) a peptide having an amino acid sequence represented by SEQ ID NO: 7, and the like, (h) a peptide having an amino acid sequence represented by SEQ ID NO: 8, and the like, (i) a peptide having an amino acid sequence represented by SEQ ID NO: 9, and the like, (j) a peptide having an amino acid sequence repre
Type:
Grant
Filed:
April 13, 2006
Date of Patent:
August 18, 2009
Assignees:
Japan as Represented by Director-General National Institute of Infectious Diseases, Denka Seiken Co., Ltd.
Abstract: The present invention provides an adjuvant that possesses a greater adjuvant potential than that of a conventional adjuvant, and that is capable of producing a protective reaction across different strains. This problem has been solved by the finding that a double-stranded RNA (for example, Poly(I:C)) unexpectedly exhibits the above capability when used in combination with a subunit antigen. Accordingly, the present invention provides a vaccine for mucosal administration containing A) a double-stranded RNA and B) a subunit antigen or inactivated antigen of a pathogen.
Type:
Application
Filed:
August 10, 2004
Publication date:
September 20, 2007
Applicants:
The Research Foundation for Microbial Diseases of Osaka University, Japan as Represented by the Director-General of National Institute of Infectious Diseases, Toray Industries, Inc.
Abstract: It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.
Type:
Application
Filed:
October 10, 2003
Publication date:
December 7, 2006
Applicants:
Osaka Bioscience Institute, JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASE
Inventors:
Yoshihiro Urade, Bruno Kubata, Pius Kabututu, Tomoyoshi Nozaki
Abstract: This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related which makes it possible to detect most SRSV-related viruses and further to distinguish their serotypes and genogroups.
Type:
Grant
Filed:
June 22, 2000
Date of Patent:
June 27, 2006
Assignees:
Japan as represented by Director-General National Institute of Infectious Diseases, Denka Seiken Co., Ltd.